Published Date:2022-03-04 Original Link:https://www.onenessbio.com/en/news_detail147_3.htm No 1 Date of announcement 2022/03/04 Time of announcement 17:13:42 Subject The Malaysia National Pharmaceutical Regulatory Agency has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon To which item it meets paragraph 10 Date of events 2022/03/04 Statement Product:ON101 Diabetic foot ulcer new drug Mass production date:NA...Read More
Published Date:2022-03-02 Original Link:https://www.onenessbio.com/en/news_detail146_3.htm No 1 Date of announcement 2022/03/01 Time of announcement 18:42:36 Subject The mechanism of action, Phase 3 MRCT results and post-market cases of the DFU new drug, Fespixon have been accepted for an oral presentation at WUWHS 2022 To which item it meets paragraph 12 Date of events 2022/03/02 Statement Date...Read More
Date 2022/03/01-05 Location Online Presentation Download Download Chinese Version Download English Version Video Recording (English interpretation) Note N/ARead More
Published Date:2022-02-25 Original Link:https://www.onenessbio.com/en/news_detail145_3.htm No 1 Date of announcement 2022/02/25 Time of announcement 17:24:16 Subject Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2022. To which item it meets paragraph 17 Date of events 2022/02/25 Statement Date of the board of directors resolution:2022/02/25 General shareholders’ meeting date:2022/05/24 General shareholders’ meeting location:Building...Read More
Published Date:2022-02-22 Original Link:https://www.onenessbio.com/en/news_detail144_4.htm No 1 Date of announcement 2022/02/22 Time of announcement 17:52:33 Subject Oneness Biotech Co., Ltd. receives a Korean patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2022/02/22 Statement Date of occurrence of the event:2022/02/22 Company...Read More
Published Date:2022-02-21 Original Link:https://www.onenessbio.com/en/news_detail143_4.htm No 1 Date of announcement 2022/02/21 Time of announcement 22:45:40 Subject The data of SNS812, an anti-Pan-COVID19 siRNA, co-developed by Oneness & MBS and supervised by NTU professors, were published today by EMBO Mol. Medicine. To which item it meets paragraph 53 Date of events 2022/02/21 Statement Date of occurrence of...Read More
Published Date:2022-02-15 Original Link:https://www.onenessbio.com/en/news_detail142_4.htm No 1 Date of announcement 2022/02/15 Time of announcement 18:03:08 Subject Oneness Biotech Co., Ltd. receives a Korean patent on the producing recombinant glycoproteins with modified glycosylation. To which item it meets paragraph 53 Date of events 2022/02/15 Statement Date of occurrence of the event:2022/02/15 Company name:ONENESS BIOTECH CO., LTD. Relationship...Read More
Published Date:2022-02-14 Original Link:https://www.onenessbio.com/en/news_detail141_4.htm No 1 Date of announcement 2022/02/14 Time of announcement 17:44:57 Subject Oneness Biotech has been invited to present at the “QIC Healthcare Forum” online investor’s conference organized by Quantum International Corporation. To which item it meets paragraph 12 Date of events 2022/02/16 Statement Date of institutional investor conference:2022/02/16~2022/02/17 Time of institutional...Read More
Published Date:2022-02-14 Original Link:https://www.onenessbio.com/en/news_detail140_4.htm No 1 Date of announcement 2022/02/14 Time of announcement 17:19:04 Subject Oneness Biotech Co., Ltd. receives an Indian patent on the producing recombinant glycoproteins with modified glycosylation. To which item it meets paragraph 53 Date of events 2022/02/14 Statement Date of occurrence of the event:2022/02/14 Company name:ONENESS BIOTECH CO., LTD. Relationship...Read More
